Tvardi Therapeutics, Inc.
TVRD
$3.75
-$0.16-4.09%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -23.65M | -23.63M | -34.77M | -29.40M | -21.04M |
| Total Depreciation and Amortization | 95.00K | 95.00K | 95.00K | 95.00K | 95.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -4.15M | -4.39M | 7.79M | 2.36M | 382.00K |
| Change in Net Operating Assets | 5.06M | 2.88M | 5.04M | 8.64M | 1.34M |
| Cash from Operations | -22.65M | -25.05M | -21.86M | -18.31M | -19.22M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -15.08M | -20.43M | -10.88M | -- | 0.00 |
| Cash from Investing | -15.08M | -20.43M | -10.88M | -- | 0.00 |
| Total Debt Issued | 28.30M | 28.30M | 28.30M | 28.30M | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 531.00K | 424.00K | 3.00K | 5.00K | 5.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 20.88M | 21.30M | -2.91M | -1.30M | -14.00K |
| Cash from Financing | 49.71M | 50.02M | 25.39M | 27.00M | -9.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 11.98M | 4.54M | -7.35M | 8.70M | -19.23M |